The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation

被引:55
作者
Filmont, Jean-Emmanuel
Gisselbrecht, Christian
Cuenca, Xavier
Deville, Laure
Ertault, Marjan
Brice, Pauline
De Kerviler, Eric
Briere, Josette
Larghero, Jerome
Moretti, Jean-Luc
Mounier, Nicolas
机构
[1] Archet Clin Univ Specialities Med, CHU Nice, F-06200 Nice, France
[2] Univ Inst Hematol, INSERM U728, St Louis Hosp, Paris, France
关键词
lymphoma; positron emission tomography; prognosis; autologous transplantation; recurrence;
D O I
10.1002/cncr.22911
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. In patients with lymphoma who had a poor prognosis, pretransplantation 18-fluorodeoxyglucose (FDG)-positron-emission tomography (PET) was important for the evaluation of response and outcome. However, little is known about the correlation of FDG-PET with post-transplantation PET The current study was designed to ascertain whether positive pretransplantation PET images are modified by the conditioning regimen. METHODS. Sixty consecutive patients who had achieved remission and underwent consolidation by autologous stem cell transplantation (ASCT) had PET images obtained before ASCT (after 3 or 4 chemotherapy cycles) and 100 days after ASCT. The correlation was explored between the presence of abnormal 18-FDG uptake (PET positive) or its absence (PET negative) and patient outcomes. RESULTS. Before ASCT, 31 patients achieved complete remission (CR), and 23 patients achieved uncertain CR. Before ASCT, 44 patients (75%) were had negative PET images; and, after ASCT, 48 patients (80%) had negative PET images. One year after ASCT, the estimated event-free survival (EFS) rate was 80% in patients who had negative pre-ASCT PET images compared with 43% in patients who had positive pre-ASCT PET images (P =.0002). The EFS rate was 81% in patients who had negative post-ASCT PET images compared with 25% in patients who had negative post-ASCT PET images (P <.0001). In multivariate analysis, only the results for pre- and post-ASCT PET images retained prognostic value, with relative risks of failure estimated at 4.9 and 11.9, respectively. CONCLUSIONS. A positive pre-ASCT PET image indicated a high risk of ASCT failure, which was increased by a positive post-ASCT PET image. For patients with lymphoma who have positive pre-ASCT PET images, more investigations using new treatment approaches will be required. For patients who have negative preASCT PET images, obtaining post-ASCT PET images does not seem to be mandatory.
引用
收藏
页码:1361 / 1369
页数:9
相关论文
共 35 条
  • [1] Involved-field radiotherapy for advanced Hodgkin's lymphoma
    Aleman, BMP
    Raemaekers, JMM
    Tirelli, U
    Bortolus, R
    van't Veer, MB
    Lybeert, MLM
    Keuning, JJ
    Carde, P
    Girinsky, T
    van der Maazen, RWM
    Tomsic, R
    Vovk, M
    van Hoof, A
    Demeestere, G
    Lugtenburg, PJ
    Thomas, J
    Schroyens, W
    De Boeck, K
    Baars, JW
    Kluin-Nelemans, JC
    Carrie, C
    Aoudjhane, M
    Bron, D
    Eghbali, H
    Smit, WGJM
    Meerwaldt, JH
    Hagenbeek, A
    Pinna, A
    Henry-Amar, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) : 2396 - 2406
  • [2] ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023
  • [3] BELHADJ K, 2006, BLOOD, P108
  • [4] Buchmann I, 2001, CANCER, V91, P889
  • [5] CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD
    CANELLOS, GP
    ANDERSON, JR
    PROPERT, KJ
    NISSEN, N
    COOPER, MR
    HENDERSON, ES
    GREEN, MR
    GOTTLIEB, A
    PETERSON, BA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) : 1478 - 1484
  • [6] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [7] Revised response criteria for malignant lymphoma
    Cheson, Bruce D.
    Pfistner, Beate
    Juweid, Malik E.
    Gascoyne, Randy D.
    Specht, Lena
    Horning, Sandra J.
    Coiffier, Bertrand
    Fisher, Richard I.
    Hagenbeek, Anton
    Zucca, Emanuele
    Rosen, Steven T.
    Stroobants, Sigrid
    Lister, T. Andrew
    Hoppe, Richard T.
    Dreyling, Martin
    Tobinai, Kensei
    Vose, Julie M.
    Connors, Joseph M.
    Federico, Massimo
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
  • [8] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [9] Utility of FDG-PET scanning in lymphoma by WHO classification
    Elstrom, R
    Guan, L
    Baker, G
    Nakhoda, K
    Vergilio, JA
    Zhuang, H
    Pitsilos, S
    Bagg, A
    Downs, L
    Mehrotra, A
    Kim, S
    Alavi, A
    Schuster, SJ
    [J]. BLOOD, 2003, 101 (10) : 3875 - 3876
  • [10] Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy:: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial
    Fermé, C
    Mounier, N
    Diviné, M
    Brice, P
    Stamatoullas, A
    Reman, O
    Voillat, L
    Jaubert, J
    Lederlin, P
    Colin, P
    Berger, F
    Salles, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 467 - 475